Syntermed anticipates NeuroQ approval

Article

A software platform consisting of quantitative tools for the analysis of brain PET scans has just been submitted to the FDA, but its maker, Syntermed, is already looking forward to marketing the product. The company expects commercial release in the

A software platform consisting of quantitative tools for the analysis of brain PET scans has just been submitted to the FDA, but its maker, Syntermed, is already looking forward to marketing the product. The company expects commercial release in the third quarter for the NeuroQ software, which rapidly and automatically quantifies more than 200 standardized regions of interest. It compares activity in those brain regions to regional activity values derived from a database of normal scans.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.